New hip resurfacing device tracked for 10 years
Disease control
Recruiting now
This study follows 150 people aged 18 to 65 who receive a ROMAX hip resurfacing implant to treat hip arthritis or congenital hip dysplasia. Researchers will monitor how long the implant lasts and measure hip function and patient satisfaction over 10 years. The goal is to confirm …
Sponsor: Medacta International SA • Aim: Disease control
Last updated Apr 24, 2026 16:19 UTC